Allogeneic CAR T-cells patented by Celyad

October 26, 2015 News BioVox

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better recognize and fight cancerous cells. The use of allogeneic CAR T-cells in comparison to autologous cells, allows the development and manufacturing of “off-the-shelf” treatments for several diseases.

Learn more about the CAR T-cell technology in BioVox’ insight article about this topic.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts